Key Highlights
- Thermo Fisher Scientific shares are trading at $659.43 in Thursday's session, down 2.31%.
- No company-specific negative has been identified behind the decline.
- The stock has rallied about 47% over the past year, drawing valuation scrutiny, and insider selling totaled roughly $158 million over 12 months.
- Third-quarter results are due on October 21, following a second quarter in which Revenue grew 10% to $11.99 billion.
No Bad News, but a Stretched Chart Invites Selling
Thermo Fisher Scientific (NYSE:TMO) is trading lower in Thursday's session, slipping to about $659 and underperforming a soft healthcare sector. No company-specific negative has been identified, which points to valuation and market conditions as the drivers.
The broader market is also lower at the start of the fourth quarter, with the 10-year Treasury Yield near 5.3% and oil elevated, a combination that tends to pressure high-multiple stocks.
A 47% Run Leaves Little Cushion
The shares have climbed about 47% over the past year and sit within reach of their 52-week high of $683.63. Valuation screens now flag the stock as modestly Overvalued against its own five-year median multiple, and roughly $158 million of insider selling over the past 12 months has added to the cautious tone.
Second-Quarter Strength Sets the Bar for October 21
The most recent Quarterly Report showed revenue growth of 10% to $11.99 billion and adjusted EPS up 13% to $6.03. Management has pointed to accelerating pharma and biotech demand, particularly in bioproduction and clinical research.
Third-quarter results on October 21 will test whether that momentum can justify the premium the market has assigned.
FAQs
Q: Why is Thermo Fisher Scientific stock down today?
A: No company-specific negative has been identified. The decline appears tied to valuation scrutiny after a roughly 47% yearly rally, a soft healthcare sector and elevated Treasury yields.
Q: When does Thermo Fisher Scientific report third-quarter earnings?
A: The company is scheduled to report third-quarter results on October 21.
Q: How did Thermo Fisher Scientific perform in the second quarter?
A: Revenue grew 10% to $11.99 billion and adjusted EPS rose 13% to $6.03.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.